Tiba Biotech
Advanced RNA vaccines and therapeutics using biodegradable nanoparticle delivery for safer, more potent gene expression.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$2.0m | Seed | ||
| Total Funding | 000k | ||
Related Content
Tiba Biotech is a pioneering company in the RNA medicine field, focusing on the development of next-generation RNA vaccines and therapeutics. The company operates in the biotechnology sector, serving clients ranging from government agencies to pharmaceutical companies. Tiba Biotech's core innovation lies in its fully biodegradable nanoparticle delivery platform, which ensures safer and more effective delivery of RNA-based treatments. This platform is complemented by computational RNA design, which enhances gene expression potency, leading to better patient outcomes.
The business model of Tiba Biotech revolves around research and development, leveraging government-sponsored research and strategic partnerships to advance its technology. The company generates revenue through collaborations, licensing agreements, and potentially through the commercialization of its proprietary RNA delivery systems and therapeutics.
Tiba Biotech's market includes applications in vaccines, particularly focusing on pressing health challenges such as the COVID-19 pandemic and seasonal influenza. By integrating advanced RNA design with state-of-the-art nanoparticle delivery, the company aims to enable life-saving vaccines and open new therapeutic avenues.
Keywords: RNA medicine, biodegradable nanoparticles, gene expression, vaccines, therapeutics, biotechnology, computational design, COVID-19, influenza, government research.